| abstract |
The present invention relates to a method for reducing C-reactive protein in a subject at risk of or already suffering from a vascular disease, or a subject suffering from an inflammatory disease. In one embodiment, the vascular disease is a cardiovascular disease (eg, myocardial infarction). In other embodiments, the vascular disease is a cerebrovascular disease (eg, stroke) (in particular, a transient ischemic attack (TIA)). In another embodiment, the vascular disease is a peripheral vascular disease (eg, intermittent) The method comprises administering a therapeutically effective amount of at least one growth hormone secretagogue compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof. Hormonal secretagogue compounds, HMG CoA reductase inhibitors, ACAT inhibitors, CETP inhibitors, anti-inflammatory agents, ACE inhibitors, beta blockers, cholesterol absorption inhibitors, nicotinic acid, fibric acid derivatives, bile acid sequestration It may be administered concurrently with the agent or a combination thereof. |